Key result
Management of spontaneous internal jugular vein thrombosis typically involves early imaging and anticoagulation with low molecular weight heparin followed by oral coumarin for 3 to 6 months to prevent complications.
Spontaneous internal jugular vein thrombosis is a rare condition that requires early diagnosis and active treatment, typically with anticoagulation, to prevent significant morbidity and mortality.
Supports anticoagulation to avert morbidity in rare spontaneous IJV thrombosis; leaves open optimal regimen and duration pending prospective trials.
Internal Jugular Vein (IJV) thrombosis is a rare but potentially fatal condition. First described in 1912 as a complication of peritonsillar abscess 1 it is now known to have a varied aetiology. The leading cause of IJV thrombosis is the use of the IJV for venous access 2 and central venous catheterization. Other causes include oropharyngeal infection (Lemierre Syndrome), deep neck space infection and trauma. It can also occur as a complication of head and neck malignancy, and rarely can be the first manifestation of the disease. On other occasions a specific aetiology is never found.
No takes yet. Share an insight, caveat, or question.
Muhammad Shakeel (2015) conducted a review in Spontaneous internal jugular vein thrombosis (n=22). Anticoagulation (Low molecular weight heparin and warfarin) was evaluated on Resolution of thrombosis and prevention of complications. Management of spontaneous internal jugular vein thrombosis typically involves early imaging and anticoagulation with low molecular weight heparin followed by oral coumarin for 3 to 6 months to prevent complications.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: